Over the last two decades, serum KL-6 has been widely investigated as a biomarker for assessing disease severity in ILD, mainly in patients with IPF and connective tissue disease (CTD)-associated ILD [17,18,19,20,21]. Here, MUC1 is linked to interstitial lung disease.